Every 8-K that Orthofix Medical Inc. (OFIX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow OFIX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full OFIX filings page.
Orthofix Medical reported Q2 2026 net sales of $210.9 million, up 3.8% on a reported basis and 4.7% on a pro forma constant-currency basis versus Q2 2025. Growth was driven by double‑digit constant‑currency increases in Global Spine Fixation and Global Limb Reconstruction, 3% growth in Therapeutic Solutions, and stabilizing Biologics.
GAAP gross margin was 71.0%, or 71.7% on an adjusted basis. The company recorded a net loss of $15.8 million, or $0.39 per share, slightly wider than a year ago, while non‑GAAP adjusted EBITDA was $20.1 million, or 9.6% of pro forma net sales, modestly below the prior-year quarter. Cash, cash equivalents and restricted cash were $104.4 million at June 30, 2026, with long‑term debt of $221.6 million; cash declined sequentially mainly due to arbitration award and settlement payments to former executives.
Reflecting Q2 performance and restored Medicare reimbursement for non‑invasive bone growth stimulators, Orthofix raised its 2026 non‑GAAP pro forma guidance to net sales of $845–$855 million and adjusted EBITDA of $95–$98 million, which at the midpoint implies about 5% constant‑currency revenue growth and 80 basis points of adjusted EBITDA margin expansion versus 2025.
Orthofix Medical Inc. reported a regulatory update affecting its non-invasive bone growth stimulators. The FDA reclassified these devices from Class III to Class II on April 16, 2026. After initially changing billing rules from May 18, 2026, CMS later reversed course.
On July 1, 2026, CMS issued revised guidance directing that Medicare claims for devices billed under HCPCS codes E0747, E0748 and E0760 from May 18, 2026 onward be processed and paid as they were before the FDA reclassification. The company currently expects average Medicare reimbursement for these codes to return to pre–May 18, 2026 levels, though it cautions that actual results depend on how the revised rules are implemented and on future claim volumes and payer behavior.
Orthofix Medical Inc. reported results of its 2026 Annual Meeting of Shareholders and approval of an amendment to its employee stock purchase plan. Shareholders approved Amendment No. 5 to the Second Amended and Restated Stock Purchase Plan, increasing the number of common shares available for issuance under the plan by 1,250,000 shares, with no other changes to the plan’s terms.
The company also confirmed that a quorum was present, with 34,776,676 common shares represented out of 40,385,869 shares eligible to vote as of the April 13, 2026 record date. Shareholders voted on the election of directors, with each listed nominee receiving substantially more votes “for” than “against,” and certain votes counted as broker non-votes for specified items.
Orthofix Medical Inc. is updating its outlook after Medicare reimbursement changes for non-invasive bone growth stimulators. Following an FDA reclassification of these devices to Class II and related CMS billing updates effective May 18, 2026, the company expects average Medicare reimbursement for key HCPCS codes to decline by about 10%.
Orthofix now projects full-year 2026 net sales of $838–$848 million and non-GAAP adjusted EBITDA of $90–$93 million, and it does not expect positive free cash flow for 2026. The company has withdrawn its three-year financial targets and will continue assessing the long-term effects of current and future CMS actions.
Orthofix Medical Inc. reported first-quarter 2026 results that show modest growth and improved bottom-line performance while reaffirming its full-year outlook. Reported net sales were $196.7 million, up 1.6% year over year, with non-GAAP pro forma net sales of $196.4 million, up 2.7% on a constant currency basis as spine distributor transitions tapered off.
Global Spine Fixation grew 6% and Therapeutic Solutions grew 5% year over year on a constant currency basis, while Global Limb Reconstruction net sales rose 3%. GAAP net loss narrowed to $20.9 million, or $(0.52) per share, compared with a net loss of $53.1 million, or $(1.35) per share, a year earlier.
Non-GAAP pro forma adjusted EBITDA was $9.7 million, or 4.9% of pro forma net sales, versus $11.4 million, or 6.0%, reflecting geography mix and commercial transitions. Cash, cash equivalents, and restricted cash increased to $120.9 million as of March 31, 2026, helped by financing activities, while free cash flow was negative $28.3 million. The company reaffirmed 2026 guidance for net sales of $850–$860 million, non-GAAP adjusted EBITDA of $95–$98 million, and positive full-year free cash flow excluding any potential legal settlements.
Orthofix Medical Inc. reported preliminary first quarter 2026 net sales of approximately $196.7 million, with non-GAAP pro forma net sales of about $196.4 million, reflecting 0.4% reported growth and 3% constant currency pro forma growth versus Q1 2025. The company reaffirmed its 2026 outlook, guiding full-year net sales between $850 million and $860 million, implying about 5.5% pro forma constant currency growth at the midpoint, non-GAAP adjusted EBITDA of $95–$98 million, and positive free cash flow excluding potential legal settlements. Orthofix also announced a strategic realignment of its Spine leadership, eliminating the President, Global Spine Solutions role so key spine leaders now report directly to the CEO, and disclosed that President, Global Spine Max Reinhardt will depart around June 12, 2026, with severance benefits under his existing agreement.
Orthofix Medical Inc. reported steady 2025 growth with improving profitability. Net sales reached $219.9 million in Q4 2025, up 2% year over year, and $822.3 million for the full year, up 2.9%. Pro forma constant-currency net sales grew 3.1% in Q4 and 4.1% for the year.
The company sharply narrowed its Q4 net loss to $2.2 million from $29.1 million, and full-year net loss to $92.2 million from $126.0 million. Non-GAAP pro forma adjusted EBITDA rose to $29.2 million in Q4 (13.4% margin) and $85.9 million for 2025 (10.6% margin), both higher than 2024. Q4 free cash flow was a strong $16.8 million, with near breakeven free cash flow for the year and positive $3.1 million excluding M6-related restructuring.
For 2026, Orthofix guides to net sales of $850–$860 million, non-GAAP adjusted EBITDA of $95–$98 million, and positive free cash flow. Updated 2026–2028 targets call for 6.5–7.5% annual net sales growth, mid-teens adjusted EBITDA margin by 2028, and sustained positive free cash flow.
Orthofix Medical Inc. (OFIX) furnished an update on its business by announcing third‑quarter results for the period ended September 30, 2025 via a press release attached as Exhibit 99.1. The company also furnished an investor relations presentation as Exhibit 99.2. These materials were furnished under Items 2.02 and 7.01 and are not deemed “filed.”
The update outlines non‑GAAP frameworks used by management, including constant currency, free cash flow, adjusted gross profit/margin, adjusted net income (loss), adjusted operating and non‑operating expenses, EBITDA and adjusted EBITDA. It also notes a long‑term normalized effective tax rate assumption of 28% for 2024 and 2025 and lists typical adjustments such as share‑based compensation, merger and restructuring costs, and items related to the discontinued M6 artificial disc product lines.
Orthofix Medical Inc. (Nasdaq: OFIX) filed an 8-K on 5 Aug 2025 to furnish, rather than file, its second-quarter 2025 earnings press release (Ex. 99.1) and an investor-relations slide deck (Ex. 99.2). The core 8-K text contains no quantitative results; all GAAP and non-GAAP figures must be obtained from the attached exhibits.
The company reiterates its extensive suite of non-GAAP metrics—constant-currency sales, free cash flow, adjusted gross profit/margin, adjusted operating & non-operating expenses, EBITDA and adjusted EBITDA—and enumerates the permitted adjustments such as share-based compensation, SeaSpine merger costs, litigation, succession charges and M6 product-line restructuring. Management argues these measures enhance period-over-period comparability, yet acknowledges their analytical limitations and provides GAAP reconciliations in the exhibits.
No guidance, outlook or numerical performance data appear in the filing itself; therefore the market impact will depend on figures contained in Exhibit 99.1.
Orthofix Medical Inc. (OFIX) filed a Form 8-K reporting the results of its 18 June 2025 Annual Meeting of Shareholders.
Quorum: 35,364,307 of 39,180,306 eligible shares were present, comfortably exceeding the 19,590,154-share quorum requirement.
Director elections: All ten nominees—Alan L. Bazaar, Wayne Burris, Massimo Calafiore, Vickie L. Capps, Michael M. Finegan, Jason M. Hannon, John B. Henneman III, Charles R. Kummeth, Shweta Singh Maniar and Michael E. Paolucci—were elected for one-year terms ending at the 2026 meeting. Each candidate received substantially more “For” than “Against” votes.
Say-on-Pay: The advisory resolution approving executive compensation passed with 30,003,045 votes in favour versus 610,731 against and 9,569 abstentions.
Auditor ratification: Shareholders ratified Ernst & Young LLP as independent auditor for fiscal 2025 (35,017,551 votes in favour; 329,289 against; 17,467 abstentions).
Board committee appointments: Effective immediately, the Board unanimously appointed director Vickie L. Capps to the Audit & Finance Committee and to the Compensation & Talent Development Committee.
The filing contains no financial results, strategic transactions or other material events beyond routine governance disclosures.